---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-25-023154"
form_type: "8-K"
ticker: "VNDA"
cik: "0001347178"
company_name: "Vanda Pharmaceuticals Inc."
filed_at: "2025-05-07T23:59:59+00:00"
generated_at: "2026-05-22T07:22:04.233128+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Vanda Q1 net loss widens to $29.5M; Fanapt sales up 14% but PONVORY down 18%

## Summary
- Net product sales $50.0M (+5% YoY); net loss $29.5M vs $4.1M loss a year ago.
- Diluted EPS -$0.50; loss reflects $15M imsidolimab license fee and higher commercial spend.
- Fanapt sales $23.5M (+14%), HETLIOZ $20.9M (+4%), PONVORY $5.6M (-18%).
- Cash $340.9M; full-year guidance: revenues $210-250M, year-end cash $280-320M.
- Tradipitant NDA PDUFA Dec 30, 2025; Bysanti NDA PDUFA Feb 21, 2026; imsidolimab BLA expected 2025.

## SEC filing metadata
- accession: 0001628280-25-023154
- form_type: 8-K
- ticker: VNDA
- cik: 0001347178
- company_name: Vanda Pharmaceuticals Inc.
- filed_at: 2025-05-07T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1347178/000162828025023154/0001628280-25-023154-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1347178/000162828025023154/vnda-20250507.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-25-023154
- JSON: https://secwatch.observer/filing/0001628280-25-023154.json
- Plain text: https://secwatch.observer/filing/0001628280-25-023154.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.